Kala Bio targeting CHASE Phase 2b data for KPI-012 (PCED) by end of 2024

KALA BIO, Inc.

Topline safety and efficacy data from CHASE Phase 2b trial expected by year-end 2024.
KPI-012 is a human mesenchymal stem cell secretome for persistent corneal epithelial defect.
Corporate presentation posted on investors section of company website; no other material updates.
No financial guidance or operational changes disclosed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.